TRKing sarcomas for precision medicine: Seek, and ye shall find!
Provider
Cell Reports Medicine
Clinical development and management of adverse events associated with FGFR inhibitors
Future Oncology
Plain language summary of the TOPAZ-1 study: durvalumab and chemotherapy for advanced biliary tract cancer
Trends in Cancer
Variant allele frequency: a decision-making tool in precision oncology?
Journal of Clinical Oncology
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy
JCO Precision Oncology
Exceptional Responses to Selpercatinib in RET Fusion-Driven Metastatic Pancreatic Cancer
Cancer Discovery
RLY-4008, the first highly selective FGFR2 inhibitor with activity across FGFR2 alterations and resistance mutations
JCO Precision Oncology
Phase IIa Study of PLX2853 in Gynecologic Cancers With Known ARID1A Mutation and Phase Ib/IIa Study of PLX2853/Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Lancet Oncology
Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study
Journal of Clinical Oncology
Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation